SC
CLRB icon

Scotia Capital’s Cellectar Biosciences CLRB Stock Holding History

Scotia Capital’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-38
Closed -$5K – 790
2022
Q2 		$5K Sell
38
-1
-3% -$143 ﹤0.01% 806
2022
Q1 		$8K Buy
39
+1
+3% +$175 ﹤0.01% 873
2021
Q4 		$8K Buy
38
+1
+3% +$241 ﹤0.01% 867
2021
Q3 		$10K Buy
+37
New +$11.3K ﹤0.01% 851

Other funds holding CLRB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $127M AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Scotia Capital's CLRB Position: Q3 2022 in Review

Scotia Capital sold out of Cellectar Biosciences (CLRB) in Q3 2022, closing a stake of 38 shares — an estimated $5K sold.

Scotia Capital first reported a position in CLRB in Q3 2021 and held it in 4 quarters. The position peaked at $10K in Q3 2021. 20 funds tracked by Wall St. Rank hold CLRB as of Q3 2022.

  • Scotia Capital reported no remaining Cellectar Biosciences position as of Q3 2022 after selling out during the quarter.
  • Scotia Capital sold 38 Cellectar Biosciences shares in Q3 2022, an estimated $5K.
  • Scotia Capital first reported a position in Cellectar Biosciences in Q3 2021 and held it in 4 quarters.
  • Scotia Capital's Cellectar Biosciences position peaked at $10K in Q3 2021.
  • 20 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q3 2022.

Based on Scotia Capital's 13F filing for Q3 2022, filed 10 Nov 2022.